Datavault AI Inc. (Nasdaq: DVLT) announced today a landmark $150 million strategic investment agreement with Scilex Holding Company (Nasdaq: SCLX), a transaction structured uniquely in Bitcoin at spot prices via Coinbase. The deal, set to unfold in two tranches—an immediate $8.07 million closing on September 26, 2025, followed by $141.93 million pending shareholder approval—positions Datavault AI at the center of a powerful convergence of biotech, AI, and blockchain technologies.
The significance of this agreement lies not only in its scale but also in its strategic direction. For Datavault, the capital will accelerate the build-out of its supercomputing infrastructure, strengthen blockchain-secured data exchanges, and drive forward its portfolio of revenue-generating platforms, including the International Elements Exchange, the International NIL Exchange, and the American Politics Exchange. For Scilex, a biotech player led by Henry Ji, Ph.D., the deal reflects a conviction that the next wave of life sciences innovation will be inseparable from AI-driven insights and scalable, trust-centric data monetization. Ji emphasized that biotech’s future demands the kind of analytics and computing precision Datavault offers, signaling Scilex’s intent not only as a financier but also as an active guide in shaping Datavault’s biotech market expansion.
CEO Nathaniel Bradley of Datavault AI underscored that this infusion of resources bolsters partnerships with the U.S. Department of Energy’s Brookhaven National Laboratory and IBM’s WatsonX ecosystem, embedding the company deeper into the national AI and supercomputing infrastructure narrative. The combination of blockchain for verifiable trust, AI for actionable insights, and Web 3.0 frameworks for monetization places Datavault in a position to serve industries where data security and integrity are paramount, from energy and natural resources to entertainment and, most prominently, biotech. With the global AI market projected at $1.8 trillion by 2030 and life sciences analytics forecasted to expand from $35.7 billion in 2024 at an 11.4% CAGR, the addressable opportunity is immense.
The terms of the investment reflect both ambition and discipline. Scilex will ultimately receive nearly 279 million Datavault shares at an effective price of $0.5378 per share, split between stock and a pre-funded warrant. Restrictions on share issuance and variable-rate transactions ensure deal stability, while Scilex secures the right to participate in future financings and to nominate up to two board members, embedding governance influence alongside its capital. The second tranche, requiring shareholder approval to exceed Nasdaq’s 19.99% issuance threshold, will be a pivotal moment for Datavault’s investors, effectively determining whether this deal fully materializes.
The transaction is notable not only for its scale and structure but also for what it signals: the rising centrality of AI-powered platforms in biotech and beyond. By intertwining digital trust mechanisms with advanced analytics and supercomputing, Datavault AI and Scilex are attempting to craft a blueprint for how cross-sector partnerships can unlock new global revenue streams. If successful, this deal may stand as an early exemplar of how Bitcoin-settled, AI-driven strategic financing reshapes the market landscape.